'Peaceful transition to Military Power....'

Cannon
44
....heard around the world

NG - High Alert https://t.co/lfeSiUCCRB

(1 of 2) Paul Manafort—a longtime associate of Howard Liebengood Sr.—is an exec at Event Strategies, which planned the 1/6 rally that ended with a breach of security at the Capitol, where Howard Liebengood Jr. worked security (USCP). 2 days later Liebengood Jr. committed suicide.

(2 of 2) I believe this is a coincidence. That said, because I don't think Manafort aiding and abetting a rally that ended in insurrection is coincidence, I have to assume that—out of an abundance of caution—law enforcement will investigate any possible Manafort-Liebengood link.

(PS) It is vital that no one presume connections where there may be none. My point is that as a criminal investigative matter, Manafort will be investigated for any role he had in the Save America March, and Liebengood's suicide would naturally be investigated due to its context.

(PS2) I'm sure there'll be those who say that a Donald Trump event giving tons of money to a company that enriches Paul Manafort at a time when Trump continues to need Manafort to stay quiet and Manafort is having money problems is a mere coincidence.

*That* I do not agree with.

(PS3) By the same token, as a federal criminal investigative matter, when you are about to have numerous investigations into whether security at a government building had been pre-compromised and someone who worked security at that building commits suicide, it gets investigated.

I've been seeing a lot of discussion around the dosage gaps recommended by government for the Astra/Oxford & Pfizer/BioNTech vaccines. My thoughts on the potential benefits & risks of such an approach, and the need for much greater transparency around these decisions. Thread.

The UK govt announced recently that both the Oxford & BioNTech vaccines would be now administered with a gap of between 4-12 weeks (so prioritise administration of first dose, given limited resources).

What is the basis of this?

The basis that's been discussed seems to be that
1) the first dose is likely to confer some degree of protection against disease, so better to roll this out as fast as possible, and
2) that for Oxford/Astra efficacy may be higher when the gap between doses is greater.

I discuss some of the technical details around the Oxford trial below for those interested in these. If you'd just like a summary of this, please skip to the summary tweet titled 'SUMMARY'.

What does published evidence show? The Astra/Oxford data are a bit messy because of protocol changes during the trial. This is because the trial was originally planned as a single dose trial, but a booster dose was added when developers realised that this would likely help.